Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01267448 · ClinicalTrials.gov registry record · Phase 4
Outpatient Discharge Therapy With Saxagliptin+MetforminXR vs GlipizideXL for Type 2 Diabetes With Severe Hyperglycemia
A Phase 4 study, sponsored by Cook County Health.
- Completed
- Registry status
- Phase 4
- Development phase
- 100
- Enrollment target
NCT01267448 is a Phase 4 study that has completed, run by Cook County Health. The registered enrollment target is 100 participants.
The verdict
NCT01267448, a Phase 4 study, has completed, sponsored by Cook County Health.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 100 participants
- Enrollment target
Study Summary
Saxagliptin + Metformin XR (S+M) will be effective in stabilizing blood glucose (BG) levels in patients with newly diagnosed type 2 diabetes (T2DM) with severe hyperglycemia (BG levels 300 to 450 mg/dl) and glucose toxicity and with no criteria for inpatient admission or occurrence of severe hypoglycemia compared to glipizide XL. The study may provide preliminary evidence to support the role of S+M as a bridging, stabilizing and safe therapy in patients with severe hyperglycemia
Interventions
- DRUG Metformin XR
- DRUG Glipizide XL
- DRUG Saxagliptin + Metformin XR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2014-09-09 |
| Est. Completion | 2015-07-25 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01267448
The ClinicalTrials.gov registry entry for NCT01267448 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cook County Health, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Metformin XR is the first listed.
NCT01267448 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01267448 about?
NCT01267448 is a clinical study titled "Outpatient Discharge Therapy With Saxagliptin+MetforminXR vs GlipizideXL for Type 2 Diabetes With Severe Hyperglycemia". Saxagliptin + Metformin XR (S+M) will be effective in stabilizing blood glucose (BG) levels in patients with newly diagnosed type 2 diabetes (T2DM) with severe hyperglycemia (BG levels 300 to 450 mg/dl) and glucose toxicity and with no criteria for inpatient admission or occurrence of severe hypogly...
What is the current status of trial NCT01267448?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2014-09-09. Estimated completion is 2015-07-25.
What interventions are being tested in trial NCT01267448?
The interventions under investigation include: Metformin XR (DRUG), Glipizide XL (DRUG), Saxagliptin + Metformin XR (DRUG).
Who is sponsoring clinical trial NCT01267448?
This trial is sponsored by Cook County Health, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.